The Beacon

By H. Jack West, MD

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about The Beacon:

How many episodes does The Beacon have?

The podcast currently has 75 episodes available.

The Beacon episodes:

May 11, 2018 Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).
...more
10min
May 10, 2018 Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)
Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).
...more
14min
May 04, 2018 KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Negative (sub 1%) Tumor PD-L1 Expression (BMIC-033)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (
...more
7min
May 04, 2018 KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.
...more
7min
April 30, 2018 KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and High (≥50%) Tumor PD-L1 Expression (BMIC-031)
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients.
...more
8min
April 27, 2018 KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advanced non-squamous NSCLC with any PD-L1 expression.
...more
14min
April 12, 2018 Is Chemotherapy More Effective After Prior Immunotherapy? (BMIC-029)
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise.
...more
6min
April 10, 2018 New Insights on Acquired Resistance to Immune Checkpoint Inhibitors for NSCLC: Implications for Treatment Options (BMIC-028)
Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced NSCLC, along with the clinical implications of various options based on these observations.
...more
12min
April 06, 2018 Is immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back. (BMIC-027)

Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective.
...more
11min
April 04, 2018 Chemo/Immunotherapy in Advanced Squamous NSCLC: What is the Impact of IMpower131? (BMIC-026)
Dr. Jack West reviews the preliminary positive result form the IMpower131 trial of chemo +/- atezolizumab immunotherapy and considers what the clinical significance of these findings should be for patients with advanced squamous NSCLC.
...more
10min

FAQs about The Beacon:

How many episodes does The Beacon have?

The podcast currently has 75 episodes available.